You searched for "surgery"
(Not very) clean intermittent self catheterisation
In a small room near the operating theatre of the London Hospital sometime in the 1880’s, a surgeon slips off his outdoor frock coat. From his pocket he pulls a silver curved catheter, spits on it and nonchalantly passes it...Indeterminate renal lesions – a pragmatic imaging approach
The incidence of renal cell carcinoma (RCC) in the UK has increased steadily over the last two decades, largely driven by the increasing use of abdominal imaging and the incidental detection of small renal lesions [1]. The majority of incidental...Initial impressions of urology in the UK from overseas trainees
Readers of Urology News will be familiar with descriptions of overseas visits by UK-based urological trainees, but it is sometimes beneficial to reflect on the experience of international medical graduates (IMGs) who elect to come to work and train in...
Solifenacin for children and adolescents with overactive bladders
Solifenacin (VESIcare®) is the second-line anti-muscarinic medication of choice for my patients with overactive bladder (oxybutynin being my initial choice). However, currently, it remains unlicensed for use in children. Newgreen et al. have evaluated the long-term safety and efficacy of...
The challenge of psychological problems in enuresis treatment
The first sentence of the conclusion of this review article reads: “In the past decade the role of psychological factors in the pathogenesis of nocturnal enuresis has changed from a primary causal factor to a consequence or comorbidity.” The authors...
Dual therapy for OAB in children
Overactive bladder (OAB) is a disorder frequently encountered by the paediatric urologist. Morin et al. report the results of the first known study on the efficacy of mirabegron (a β3 adrenoceptor agonist) as add-on therapy in paediatric patients with refractory...
Solifenacin and mirabegron are safe and effective in combination
Antimuscarinic agents remain the mainstay of medical management of bladder overactivity. Limited somewhat by their tolerability, the new agent mirabegron, a β3-adrenoreceptor agonist, has been approved as an alternative. There is little known however about the possible synergistic effects of...
